Increasing Prevalence/Incidence of Obesity to Augment the Orlistat Market Growth

 

Orlistat Market

Orlistat, also known as Xenical, is a dietary supplement that has recently gained the Food and Drug Administration (FDA) approval. This herb, which also goes by the names Phentermine and Orlistat, was originally developed to help people who suffer from acid reflux and heartburn, but it's recently been used to help people lose weight. Orlistat helps suppress the appetite and stimulates the release of serotonin. This reduces the desire for food and helps increase the number of calories burned during exercise. It can be purchased over-the-counter and comes in various flavors, such as butterscotch, raspberry, orange, and chocolate.

Orlistat is a type of drug designed to treat obesity. The primary function of orlistat is to inhibit the absorption of fat from the diet consumed by humans. Moreover, orlistat helps prevent the onset of type 2 diabetes and reduce blood pressure in obese people. Orlistat does not allow one to regain lost weight and does not block the absorption of fats from non-fat foods and sugar.

Market Dynamics

Increasing prevalence of obesity worldwide is expected to fuel the growth of the orlistat market. For instance, around 38 million children aged 5 years or less were overweight or obese in 2019, according to the World Health Organization (WHO). Obesity is defined as having a body-mass index equal to or greater than 30.

Moreover, increasing demand for orlistat, as well as speedy approvals by regulatory authorities for biosimilars, especially in North America, are expected to propel the growth of the orlistat market. For instance, in December 2020, Novo Nordisk received the U.S. Food and Drug Administration (FDA) approval for Saxenda (liraglutide) injection for the treatment of obesity in adolescents (aged 12 to 17 years) with a body weight above 60 kg.

Launch of new generic version of orlistat and increasing number of awareness campaigns for weight management are also expected to drive the orlistat market growth.

Competitive Analysis

Major players operating in the orlistat market are Kabir Life Sciences and Research Pvt. Ltd., China Zhongshan Pharma, D.M. Pharma, Taj Pharmaceuticals Ltd., HISUN Pharmaceuticals Co. Ltd., ZEIN Pharmaceutical Co. Ltd., Lunan Pharmaceutical group Corporation Ltd., National Company for Pharmaceutical Industry, Hexal AG., STADA–VN J.V. Co., Sandoz Pharmaceuticals, Teva Pharmaceutical Industries, GlaxoSmithKline, and Roche Holding AG.

Major players in the market are adopting various strategies such as collaborations, partnerships, product launch, etc. to enhance their market position. For instance, in 2018, H2-Pharma and CHEPLAPHARM re-launched XENICAL (orlistat) 120 mg Capsules in the U.S. market.

Location: United States

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex...
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the d...
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood c...
Read more